- Mesoblast press release (NASDAQ:MESO): FY GAAP EPS of -$0.09 beats by $0.63.
- Revenue of $5.9M (-21.3% Y/Y) misses by $1.71M.
- Cash balance at June 30, 2024 was $63.3 million (A$95.0 million), with additional $10.0 million available from an existing facility on FDA approval of RYONCIL.
